Human leukocyte antigen-DRB1*1502 (DR2Dw 12) transgene reduces incidence and severity of arthritis in mice

Miguel A. Gonzalez-Gay, Eric Zanelli, Sanjay D. Khare, Christopher J. Krco, Paul Zhou, Hidetoshi Inoko, Marie M. Griffiths, Harvinder S. Luthra, Chella S. David

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

A strong correlation exists between susceptibility to RA in humans and some DRB1 * alleles of the MHC region such as DRB1* 0.401 and DRB1 *0101. Meanwhile, incidences of other specificities, such as DR2* DR5, or DR7 have been found reduced among RA patients. Like RA, susceptibility to mouse CIA is influenced by the MHC class II loci. To analyze the effect of a DRB1 molecule associated with low incidence of RA on mouse CIA, a human DRB1*1502 (DR2Dw12) transgene was introduced inter CIA-susceptible B10.RQB3 (H2A+1) mice. Transgene-positive DHRB1*1502 mice showed a significant reduction in the incidence and severity of arthritis. Moreover, the clinical reduction of arthritis correlated with the T-cell proliferative response of B10.RQB3- DRB1*1502 mice against a self-derived DRBI peptide from the third hypervariable region. Our results suggest that the DRB1 *1502-mediated protection against CIA can be explained by the DRBI molecule acting as a source of self-antigenic peptide which interferes with the T-cull response against immunodominant region(s) of the arthritogenic type II collagen molecule. By analogy, a similar mechanism might play a critical role in influencing the class II-associated predisposition to RA.

Original languageEnglish (US)
Pages (from-to)54-60
Number of pages7
JournalHuman Immunology
Volume50
Issue number1
DOIs
StatePublished - Sep 15 1996

Fingerprint

HLA Antigens
Transgenes
Arthritis
Incidence
Immunodominant Epitopes
Peptides
Collagen Type II
Alleles
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Gonzalez-Gay, M. A., Zanelli, E., Khare, S. D., Krco, C. J., Zhou, P., Inoko, H., ... David, C. S. (1996). Human leukocyte antigen-DRB1*1502 (DR2Dw 12) transgene reduces incidence and severity of arthritis in mice. Human Immunology, 50(1), 54-60. https://doi.org/10.1016/0198-8859(96)00123-1

Human leukocyte antigen-DRB1*1502 (DR2Dw 12) transgene reduces incidence and severity of arthritis in mice. / Gonzalez-Gay, Miguel A.; Zanelli, Eric; Khare, Sanjay D.; Krco, Christopher J.; Zhou, Paul; Inoko, Hidetoshi; Griffiths, Marie M.; Luthra, Harvinder S.; David, Chella S.

In: Human Immunology, Vol. 50, No. 1, 15.09.1996, p. 54-60.

Research output: Contribution to journalArticle

Gonzalez-Gay, MA, Zanelli, E, Khare, SD, Krco, CJ, Zhou, P, Inoko, H, Griffiths, MM, Luthra, HS & David, CS 1996, 'Human leukocyte antigen-DRB1*1502 (DR2Dw 12) transgene reduces incidence and severity of arthritis in mice', Human Immunology, vol. 50, no. 1, pp. 54-60. https://doi.org/10.1016/0198-8859(96)00123-1
Gonzalez-Gay, Miguel A. ; Zanelli, Eric ; Khare, Sanjay D. ; Krco, Christopher J. ; Zhou, Paul ; Inoko, Hidetoshi ; Griffiths, Marie M. ; Luthra, Harvinder S. ; David, Chella S. / Human leukocyte antigen-DRB1*1502 (DR2Dw 12) transgene reduces incidence and severity of arthritis in mice. In: Human Immunology. 1996 ; Vol. 50, No. 1. pp. 54-60.
@article{667ac86602194de9a76c7ccf643e2a75,
title = "Human leukocyte antigen-DRB1*1502 (DR2Dw 12) transgene reduces incidence and severity of arthritis in mice",
abstract = "A strong correlation exists between susceptibility to RA in humans and some DRB1 * alleles of the MHC region such as DRB1* 0.401 and DRB1 *0101. Meanwhile, incidences of other specificities, such as DR2* DR5, or DR7 have been found reduced among RA patients. Like RA, susceptibility to mouse CIA is influenced by the MHC class II loci. To analyze the effect of a DRB1 molecule associated with low incidence of RA on mouse CIA, a human DRB1*1502 (DR2Dw12) transgene was introduced inter CIA-susceptible B10.RQB3 (H2A+1) mice. Transgene-positive DHRB1*1502 mice showed a significant reduction in the incidence and severity of arthritis. Moreover, the clinical reduction of arthritis correlated with the T-cell proliferative response of B10.RQB3- DRB1*1502 mice against a self-derived DRBI peptide from the third hypervariable region. Our results suggest that the DRB1 *1502-mediated protection against CIA can be explained by the DRBI molecule acting as a source of self-antigenic peptide which interferes with the T-cull response against immunodominant region(s) of the arthritogenic type II collagen molecule. By analogy, a similar mechanism might play a critical role in influencing the class II-associated predisposition to RA.",
author = "Gonzalez-Gay, {Miguel A.} and Eric Zanelli and Khare, {Sanjay D.} and Krco, {Christopher J.} and Paul Zhou and Hidetoshi Inoko and Griffiths, {Marie M.} and Luthra, {Harvinder S.} and David, {Chella S.}",
year = "1996",
month = "9",
day = "15",
doi = "10.1016/0198-8859(96)00123-1",
language = "English (US)",
volume = "50",
pages = "54--60",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Human leukocyte antigen-DRB1*1502 (DR2Dw 12) transgene reduces incidence and severity of arthritis in mice

AU - Gonzalez-Gay, Miguel A.

AU - Zanelli, Eric

AU - Khare, Sanjay D.

AU - Krco, Christopher J.

AU - Zhou, Paul

AU - Inoko, Hidetoshi

AU - Griffiths, Marie M.

AU - Luthra, Harvinder S.

AU - David, Chella S.

PY - 1996/9/15

Y1 - 1996/9/15

N2 - A strong correlation exists between susceptibility to RA in humans and some DRB1 * alleles of the MHC region such as DRB1* 0.401 and DRB1 *0101. Meanwhile, incidences of other specificities, such as DR2* DR5, or DR7 have been found reduced among RA patients. Like RA, susceptibility to mouse CIA is influenced by the MHC class II loci. To analyze the effect of a DRB1 molecule associated with low incidence of RA on mouse CIA, a human DRB1*1502 (DR2Dw12) transgene was introduced inter CIA-susceptible B10.RQB3 (H2A+1) mice. Transgene-positive DHRB1*1502 mice showed a significant reduction in the incidence and severity of arthritis. Moreover, the clinical reduction of arthritis correlated with the T-cell proliferative response of B10.RQB3- DRB1*1502 mice against a self-derived DRBI peptide from the third hypervariable region. Our results suggest that the DRB1 *1502-mediated protection against CIA can be explained by the DRBI molecule acting as a source of self-antigenic peptide which interferes with the T-cull response against immunodominant region(s) of the arthritogenic type II collagen molecule. By analogy, a similar mechanism might play a critical role in influencing the class II-associated predisposition to RA.

AB - A strong correlation exists between susceptibility to RA in humans and some DRB1 * alleles of the MHC region such as DRB1* 0.401 and DRB1 *0101. Meanwhile, incidences of other specificities, such as DR2* DR5, or DR7 have been found reduced among RA patients. Like RA, susceptibility to mouse CIA is influenced by the MHC class II loci. To analyze the effect of a DRB1 molecule associated with low incidence of RA on mouse CIA, a human DRB1*1502 (DR2Dw12) transgene was introduced inter CIA-susceptible B10.RQB3 (H2A+1) mice. Transgene-positive DHRB1*1502 mice showed a significant reduction in the incidence and severity of arthritis. Moreover, the clinical reduction of arthritis correlated with the T-cell proliferative response of B10.RQB3- DRB1*1502 mice against a self-derived DRBI peptide from the third hypervariable region. Our results suggest that the DRB1 *1502-mediated protection against CIA can be explained by the DRBI molecule acting as a source of self-antigenic peptide which interferes with the T-cull response against immunodominant region(s) of the arthritogenic type II collagen molecule. By analogy, a similar mechanism might play a critical role in influencing the class II-associated predisposition to RA.

UR - http://www.scopus.com/inward/record.url?scp=0030587504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030587504&partnerID=8YFLogxK

U2 - 10.1016/0198-8859(96)00123-1

DO - 10.1016/0198-8859(96)00123-1

M3 - Article

C2 - 8872175

AN - SCOPUS:0030587504

VL - 50

SP - 54

EP - 60

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 1

ER -